Veracyte, Inc.
NASDAQ:VCYTBiotechnology
+$1.83 today
- Market cap
- $2.06B
- Beta
- 1.98
- P/E (TTM)
- 48.0
- EPS (TTM)
- $1.11
Volume 2.45M
Average 1.05M
VCYT Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Veracyte, Inc.NASDAQ: VCYT
Total Assets · Q2 FY2026 · quarter ended Jun 2026
Total assets rises 10.6% from a year ago
Total assets stood at $1.49B at the end of Q2 FY2026, up 10.6% from a year earlier and up 3.5% from the prior quarter. Over 3 fiscal years it compounded at +6.7% a year.
Context
- Total assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total assets keeps rising in the next quarterly balance sheet after a +10.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 1.41B USD
- Year-over-year change
- +8.2%
- 4-year CAGR
- +4.3%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.41B | +8.2% |
| FY2024 | 2024-12-31 | 1.3B | +16.6% |
| FY2023 | 2023-12-31 | 1.11B | -3.6% |
| FY2022 | 2022-12-31 | 1.16B | -2.6% |
| FY2021 | 2021-12-31 | 1.19B | — |
Total Assets vs competitors
How VCYT compares with its peers on the latest reported figures
- VCYT's Jun 2026 total assets of $1.49B is the 2nd highest of the 10 companies compared; the peer median is $547.81M.
- Its year-over-year change of +10.6% is the 4th highest of 10, against a peer median of +9.2%.
- Over three fiscal years its annual growth of +6.7% compares with a peer median of -0.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Sep 2026 | $1.89B | +47.7% | +7.7% | |
| Jun 2026 | $1.49B | +10.6% | +6.7% | |
| Jun 2026 | $1.35B | -3.0% | -7.9% | |
BLLNBillionToOne, Inc. | Jun 2026 | $729.7M | +133.4% | — |
| Mar 2026 | $673.7M | -33.0% | -16.2% | |
| Mar 2026 | $547.81M | +9.2% | +9.0% | |
WGSGeneDx Holdings Corp. | Jun 2026 | $481.49M | +3.8% | +1.5% |
| Mar 2026 | $325.4M | +19.1% | +4.5% | |
| Mar 2026 | $94.64M | +9.7% | -2.0% | |
IMDXInsight Molecular Diagnostics Inc. | Mar 2026 | $40.43M | -33.0% | -36.4% |
| Peer median (excluding VCYT) | $547.81M | +9.2% | -0.2% | |
Competitors are the stored peer set for VCYT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 173.2M | 154.25M | 216.45M | 239.09M | 362.58M |
| Short-term Investments | 3.96M | 24.61M | 0 | 50.35M | 50.31M |
| Net Receivables | 41.46M | 44.02M | 40.38M | 46.53M | 44.66M |
| Inventory | 11.23M | 14.29M | 16.13M | 21.75M | 20.55M |
| Other Current Assets | (3.96M) | 11.47M | 12.66M | 14.55M | 10.28M |
| Total Current Assets | 243.1M | 248.64M | 285.62M | 372.27M | 488.38M |
| Property, Plant & Equipment (Net) | 31.14M | 30.86M | 30.86M | 71.14M | 58.79M |
| Goodwill | 707.9M | 695.89M | 702.98M | 745.8M | 767.15M |
| Intangible Assets | 202.73M | 174.87M | 88.59M | 102.3M | 89.15M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2.95M | 6.17M | 6.85M | 8.53M | 2.55M |
| Total Non-current Assets | 944.72M | 907.79M | 829.29M | 927.77M | 917.64M |
| Total Assets | 1.19B | 1.16B | 1.11B | 1.3B | 1.41B |
| Account Payables | 12.36M | 11.91M | 12.94M | 8.63M | 4.59M |
| Short-term Debt | 1.13M | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 4.65M | 2.61M | 2.01M | 1.67M | 1.16M |
| Other Current Liabilities | 33.71M | 36.88M | 29.19M | 47.6M | 28.79M |
| Total Current Liabilities | 64.15M | 62.61M | 61.24M | 78.63M | 59.94M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 5.59M | 4.53M | 734K | 1.23M | 646K |
| Deferred Revenue (Non-current) | 343K | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 7.13M | 3.43M | 1.3M | 972K | 257K |
| Total Non-current Liabilities | 27.16M | 18.61M | 9.56M | 45.44M | 36.51M |
| Total Liabilities | 91.31M | 81.22M | 70.8M | 124.07M | 96.44M |
| Common Stock | 71K | 72K | 73K | 78K | 79K |
| Retained Earnings | (357.16M) | (393.72M) | (468.12M) | (443.98M) | (377.63M) |
| Accumulated OCI | (15.08M) | (31.35M) | (24.02M) | (36.09M) | (8.21M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 1.1B | 1.08B | 1.04B | 1.18B | 1.31B |
| Total Debt | 18.85M | 14.72M | 12.63M | 50.74M | 39.65M |
| Net Debt | (154.34M) | (139.53M) | (203.82M) | (188.35M) | (322.92M) |
Veracyte, Inc.
NASDAQ:VCYT
Intrinsic Alpha fair value
Locked
Current Price
$25.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.